Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

This study is testing whether a gentle form of nerve stimulation called transcutaneous auricular vagus nerve stimulation (taVNS) — delivered through a small device worn on the ear — can improve quality of life in women with ovarian cancer receiving first-line chemotherapy. The vagus nerve influences how the body handles stress and inflammation, and researchers believe stimulating it may help reduce side effects and improve wellbeing during treatment. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of epithelial ovarian cancer at stage IIB or higher - You are scheduled to start first-line chemotherapy (neoadjuvant or adjuvant) - You have given written informed consent **You may NOT be eligible if...** - You have an implanted electronic device (pacemaker, defibrillator, etc.) - You have skin problems in the ear area where the device would be placed - You have had epileptic seizures within the past 2 years - You have severe cardiovascular disease Talk to your doctor to see if this trial is right for you.